Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

Tenon Medical's $15.6M raise clears convertibles and Nasdaq risk, but not the funding question

The SI joint fusion maker used a quarter of financing to repay senior notes early and regain listing compliance. Peers' Q3 raises show how different the small-cap capital market has become.

16 Nov 2026 · CompePharma editorial

What happened

Tenon Medical, maker of the SImmetry+ and Catamaran SI joint fusion systems, reported Q3 2026 results on November 12. Revenue rose 22% to $1.4 million, gross margin was 66.3% and net loss was $6.6 million. The financing steps matter as much as the operating numbers. During the quarter Tenon raised about $15.6 million gross, repaid its senior convertible notes early and regained Nasdaq compliance.

The company also began a full commercial launch of a 3D-printed lateral screw for SImmetry+ and added eight U.S. patents. It plans a full market release of the Quickstep Decorticator in Q1 2027.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →